The Portuguese Pharmacovigilance System

Detalhes bibliográficos
Autor(a) principal: Herdeiro, Maria Teresa
Data de Publicação: 2012
Outros Autores: Ferreira, Mónica, Ribeiro-Vaz, Inês, Junqueira Polónia, Jorge, Costa-Pereira, Altamiro
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/67
Resumo: In Portugal, the National Pharmacovigilance System (NPS) was created in 1992, completing during this year 20 years of existence. Having been established in a centralized manner, it soon became aware that its geographic decentralization would bring advantages in terms of proximity of the System to health professionals as well as the involvement of the universities. The NPS currently has four regional pharmacovigilance centres, which cover the entire mainland, which became centers of scientific vocation, carrying out pharmacoepidemiological studies in the area of drug safety. Also, they are the guarantee of proper collection, processing and evaluation of spontaneous reports of adverse drug reactions (ADRs), as well as the continuing disclosure of the System among health professionals and promotion of spontaneous reporting. Over these 20 years, the NPS has been adapting to the EU requirements in the area of pharmacovigilance, and is currently a mature and well implemented system, with the objectives of the evaluation of the safety profile of marketed drugs and triggering of actions to reduce the risk of these drugs. From the second half of 2012, new adaptation will be run with the implementation of recent European legislation on Pharmacovigilance, published in December 2010. Among other changes, there is the possibility for consumers to report their suspicious of ADR directly to the NPS (exclusive, so far, to health professionals). This work aims to be a reflection about the evolution of the National Pharmacovigilance System and its growing importance in the protection of public health.
id RCAP_fe6abf686a8c585f5a2d306ae647bb42
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/67
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling The Portuguese Pharmacovigilance SystemO Sistema Português de FarmacovigilânciaIn Portugal, the National Pharmacovigilance System (NPS) was created in 1992, completing during this year 20 years of existence. Having been established in a centralized manner, it soon became aware that its geographic decentralization would bring advantages in terms of proximity of the System to health professionals as well as the involvement of the universities. The NPS currently has four regional pharmacovigilance centres, which cover the entire mainland, which became centers of scientific vocation, carrying out pharmacoepidemiological studies in the area of drug safety. Also, they are the guarantee of proper collection, processing and evaluation of spontaneous reports of adverse drug reactions (ADRs), as well as the continuing disclosure of the System among health professionals and promotion of spontaneous reporting. Over these 20 years, the NPS has been adapting to the EU requirements in the area of pharmacovigilance, and is currently a mature and well implemented system, with the objectives of the evaluation of the safety profile of marketed drugs and triggering of actions to reduce the risk of these drugs. From the second half of 2012, new adaptation will be run with the implementation of recent European legislation on Pharmacovigilance, published in December 2010. Among other changes, there is the possibility for consumers to report their suspicious of ADR directly to the NPS (exclusive, so far, to health professionals). This work aims to be a reflection about the evolution of the National Pharmacovigilance System and its growing importance in the protection of public health.O Sistema Nacional de Farmacovigilância (SNF) foi criado em 1992, completando durante o ano corrente 20 anos de existência. Tendo sido estabelecido de forma centralizada, depressa se tomou consciência que a sua descentralização geográfica traria vantagens ao nível da proximidade do Sistema aos profissionais de saúde, bem como do envolvimento das Universidades no mesmo. O SNF conta, atualmente, com quatro unidades regionais de farmacovigilância, que cobrem todo o território continental, e que se tornaram centros com vocação científica, levando a cabo alguns estudos farmacoepidemiológicos na área da segurança do medicamento. Além disso, são o garante da correta recolha, processamento e avaliação das notificações espontâneas de reações adversas a medicamentos (RAM), bem como da permanente divulgação do Sistema junto dos profissionais de saúde e promoção da notificação espontânea. Ao longo destes 20 anos, o SNF foi-se adaptando às exigências comunitárias na área da Farmacovigilância, sendo atualmente um sistema maduro e bem implementado, tendo como objetivos basilares a avaliação do perfil de segurança dos medicamentos comercializados e o desencadeamento de ações para reduzir os riscos da utilização desses medicamentos. A partir do 2º semestre de 2012, decorrerá uma nova adaptação, com a implementação da recente legislação europeia de farmacovigilância, publicada em dezembro de 2010. De entre outras alterações, destaca-se a possibilidade de os consumidores notificarem as suas suspeitas de RAM diretamente ao SNF (exclusiva, até agora, dos profissionais de saúde). Este trabalho pretende constituir uma reflexão sobre a evolução do Sistema Nacional de Farmacovigilância e a sua crescente importância na proteção da Saúde Pública.Ordem dos Médicos2012-08-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/67oai:ojs.www.actamedicaportuguesa.com:article/67Acta Médica Portuguesa; Vol. 25 No. 4 (2012): July-August; 241-249Acta Médica Portuguesa; Vol. 25 N.º 4 (2012): Julho-Agosto; 241-2491646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/67https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/67/55Direitos de Autor (c) 2012 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessHerdeiro, Maria TeresaFerreira, MónicaRibeiro-Vaz, InêsJunqueira Polónia, JorgeCosta-Pereira, Altamiro2022-12-20T10:55:47Zoai:ojs.www.actamedicaportuguesa.com:article/67Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:16:22.009324Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv The Portuguese Pharmacovigilance System
O Sistema Português de Farmacovigilância
title The Portuguese Pharmacovigilance System
spellingShingle The Portuguese Pharmacovigilance System
Herdeiro, Maria Teresa
title_short The Portuguese Pharmacovigilance System
title_full The Portuguese Pharmacovigilance System
title_fullStr The Portuguese Pharmacovigilance System
title_full_unstemmed The Portuguese Pharmacovigilance System
title_sort The Portuguese Pharmacovigilance System
author Herdeiro, Maria Teresa
author_facet Herdeiro, Maria Teresa
Ferreira, Mónica
Ribeiro-Vaz, Inês
Junqueira Polónia, Jorge
Costa-Pereira, Altamiro
author_role author
author2 Ferreira, Mónica
Ribeiro-Vaz, Inês
Junqueira Polónia, Jorge
Costa-Pereira, Altamiro
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Herdeiro, Maria Teresa
Ferreira, Mónica
Ribeiro-Vaz, Inês
Junqueira Polónia, Jorge
Costa-Pereira, Altamiro
description In Portugal, the National Pharmacovigilance System (NPS) was created in 1992, completing during this year 20 years of existence. Having been established in a centralized manner, it soon became aware that its geographic decentralization would bring advantages in terms of proximity of the System to health professionals as well as the involvement of the universities. The NPS currently has four regional pharmacovigilance centres, which cover the entire mainland, which became centers of scientific vocation, carrying out pharmacoepidemiological studies in the area of drug safety. Also, they are the guarantee of proper collection, processing and evaluation of spontaneous reports of adverse drug reactions (ADRs), as well as the continuing disclosure of the System among health professionals and promotion of spontaneous reporting. Over these 20 years, the NPS has been adapting to the EU requirements in the area of pharmacovigilance, and is currently a mature and well implemented system, with the objectives of the evaluation of the safety profile of marketed drugs and triggering of actions to reduce the risk of these drugs. From the second half of 2012, new adaptation will be run with the implementation of recent European legislation on Pharmacovigilance, published in December 2010. Among other changes, there is the possibility for consumers to report their suspicious of ADR directly to the NPS (exclusive, so far, to health professionals). This work aims to be a reflection about the evolution of the National Pharmacovigilance System and its growing importance in the protection of public health.
publishDate 2012
dc.date.none.fl_str_mv 2012-08-30
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/67
oai:ojs.www.actamedicaportuguesa.com:article/67
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/67
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/67
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/67
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/67/55
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2012 Acta Médica Portuguesa
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2012 Acta Médica Portuguesa
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 25 No. 4 (2012): July-August; 241-249
Acta Médica Portuguesa; Vol. 25 N.º 4 (2012): Julho-Agosto; 241-249
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130617740263424